Key takeaways from ACC.25: Advances in cardiovascular science
Key takeaways from ACC.25: Advances in cardiovascular science
Highlighted by AHA/ACC. April 01, 2025
1-Semaglutide’s expanding benefits
“Probably the most important presentations that resonated with me were looking at the use of semaglutide, a GLP-1 receptor agonist that originally was being used in diabetics to lower sugar and then weight loss and obesity. And now we found that it has multiple effects and we know that people on this agent can reduce cardiovascular risk. One study showed it improves patients who have chronic kidney disease. One of the first late-breaking trials showed how patients who have peripheral arterial disease and claudication when they walk, could actually have improvement in their walk time and their quality of life simply by taking these agents for a few weeks,” Wilson explained.
He also pointed to a trial for an oral replacement pill for injectable semaglutide, which performed just as well as the much more widely used injectables.
https://www.patientcareonline.com/view/acc-2025-cardiovascular-benefits-of-semaglutide-2-4-mg-highlighted-in-real-world-study?
